# BIOFORCE NANOSCIENCES HOLDINGS, INC. (BFNH) · Edgar & Edgarette company card

> Bioforce Nanosciences Holdings (BFNH) grew revenue 9.0% in FY2019 to $0 million, operating margin -262% against a -1.0% median for laboratory analytical instruments, equity 80.3% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1310488 · fiscal year ended 2019-12-31 · 3 audited years read · [page](https://www.pops4.com/boards/company/BFNH) · [JSON](https://www.pops4.com/boards/company/BFNH.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $17,775 |
| Revenue growth, 1 year | 9.0% |
| Revenue growth per year | 98.8% |
| Operating margin | -261.8% (prior year -409.2%) |
| Net margin | -261.8% |
| Operating cash flow | −$24,383 |
| Capital spending | — |
| Free cash flow | — |
| Cash | $52,895 |
| Long-term debt | — |
| Total assets | $58,895 |
| Total equity | $47,308 |
| Equity ÷ assets | 80.3% |
| Return on equity | -98.4% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -37.92 (distress zone)
- Piotroski F: 3 of 9 (middling)
- Health Harbor boat: Rotting at the dock · four or more warning signs · filed late annual report notice, late quarterly report notice in the last 12 months; liabilities exceed assets (often from years of share buybacks, not always distress); operating cash flow was negative (-$65K in FY2025); revenue is hard to predict: its 80% range is ±28%

## Edgarette's reading

Exposure: revenue $18K (FY2019). Experience: revenue up 9.0% on the year, up 98.8% a year over 2 years; operating margin -261.8%, up from -409.2%. Soundness: equity 80.3% of assets, return on equity -98.4%. Credibility: 3 audited years, moderate weight. Range: 80% of past cases like this landed between $20K and $36K next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (12 filers, $50M+ revenue, laboratory analytical instruments): operating margin -261.8% against a -1.0% median; growth 9.0% against 1.1%.

## Health Watch, last 12 months

- Item NT 10-K Late annual report notice: 1, latest 2026-03-31 ([filing](https://www.sec.gov/Archives/edgar/data/1310488/000109181826000032/0001091818-26-000032-index.htm))
- Item NT 10-Q Late quarterly report notice: 2, latest 2026-05-13 ([filing](https://www.sec.gov/Archives/edgar/data/1310488/000109181826000070/0001091818-26-000070-index.htm))
- Item 5.02 Director or officer change: 1, latest 2026-06-18 ([filing](https://www.sec.gov/Archives/edgar/data/1310488/000109181826000084/0001091818-26-000084-index.htm))

## Recent filings

- 8-K · filed 2026-10-07 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1310488/000109181826000150/0001091818-26-000150-index.htm)
- 8-K · filed 2026-09-04 · 3.02 Unregistered Sales of Equity Securities · [filing](https://www.sec.gov/Archives/edgar/data/1310488/000109181826000140/0001091818-26-000140-index.htm)
- 8-K · filed 2026-08-18 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1310488/000109181826000128/0001091818-26-000128-index.htm)
- 8-K · filed 2026-08-14 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1310488/000109181826000124/0001091818-26-000124-index.htm)
- 10-Q · filed 2026-08-10 · [filing](https://www.sec.gov/Archives/edgar/data/1310488/000109181826000108/0001091818-26-000108-index.htm)
- 8-K · filed 2026-07-07 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1310488/000109181826000089/0001091818-26-000089-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001310488.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1310488

## Cite

POPS4, Edgar & Edgarette: BIOFORCE NANOSCIENCES HOLDINGS, INC. (BFNH) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/BFNH. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Its latest audited year is FY2025, which reports no revenue; the revenue figures and the range here are from FY2019, its last year with revenue on record. Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.